CN105792824B - 色酮衍生物作为多巴胺d3受体拮抗剂用于治疗自闭症谱系障碍的用途 - Google Patents

色酮衍生物作为多巴胺d3受体拮抗剂用于治疗自闭症谱系障碍的用途 Download PDF

Info

Publication number
CN105792824B
CN105792824B CN201480066587.4A CN201480066587A CN105792824B CN 105792824 B CN105792824 B CN 105792824B CN 201480066587 A CN201480066587 A CN 201480066587A CN 105792824 B CN105792824 B CN 105792824B
Authority
CN
China
Prior art keywords
dopamine
asd
pharmaceutically acceptable
autism spectrum
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480066587.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105792824A (zh
Inventor
A·奥克莱尔
P·莫泽
P·索科洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CN105792824A publication Critical patent/CN105792824A/zh
Application granted granted Critical
Publication of CN105792824B publication Critical patent/CN105792824B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480066587.4A 2013-12-13 2014-12-12 色酮衍生物作为多巴胺d3受体拮抗剂用于治疗自闭症谱系障碍的用途 Expired - Fee Related CN105792824B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306726.4 2013-12-13
EP13306726 2013-12-13
PCT/EP2014/077635 WO2015086836A1 (en) 2013-12-13 2014-12-12 A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder

Publications (2)

Publication Number Publication Date
CN105792824A CN105792824A (zh) 2016-07-20
CN105792824B true CN105792824B (zh) 2018-08-03

Family

ID=49883003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480066587.4A Expired - Fee Related CN105792824B (zh) 2013-12-13 2014-12-12 色酮衍生物作为多巴胺d3受体拮抗剂用于治疗自闭症谱系障碍的用途

Country Status (29)

Country Link
US (1) US10028948B2 (enExample)
EP (1) EP3079688B1 (enExample)
JP (1) JP6419826B2 (enExample)
KR (1) KR102280530B1 (enExample)
CN (1) CN105792824B (enExample)
AU (1) AU2014363428B2 (enExample)
BR (1) BR112016012552A8 (enExample)
CA (1) CA2932791C (enExample)
CY (1) CY1119907T1 (enExample)
DK (1) DK3079688T3 (enExample)
ES (1) ES2657706T3 (enExample)
HR (1) HRP20180323T8 (enExample)
HU (1) HUE036035T2 (enExample)
IL (1) IL245996B (enExample)
LT (1) LT3079688T (enExample)
MA (1) MA39076A1 (enExample)
MX (1) MX372922B (enExample)
MY (1) MY172937A (enExample)
NO (1) NO3079688T3 (enExample)
NZ (1) NZ720868A (enExample)
PL (1) PL3079688T3 (enExample)
PT (1) PT3079688T (enExample)
RS (1) RS56931B1 (enExample)
RU (2) RU2686110C1 (enExample)
SA (1) SA516371298B1 (enExample)
SI (1) SI3079688T1 (enExample)
TN (1) TN2016000213A1 (enExample)
UA (1) UA117271C2 (enExample)
WO (1) WO2015086836A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101612146B1 (ko) 2008-07-16 2016-04-12 리히터 게데온 닐트. 도파민 수용체 리간드를 함유하는 약학적 제형
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2021048544A1 (en) * 2019-09-11 2021-03-18 Oxford Biodynamics Limited Diagnostic chromosome marker
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539281A1 (fr) * 1991-10-23 1993-04-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés de naphtamides, leur procédé de préparation et leur application dans le domaine thérapeutique
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
WO2000021951A1 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465A1 (fr) * 2009-09-01 2011-03-04 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
WO2011150380A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012168411A1 (fr) * 2011-06-09 2012-12-13 Pierre Fabre Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012157463A1 (en) * 2011-05-13 2012-11-22 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539281A1 (fr) * 1991-10-23 1993-04-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés de naphtamides, leur procédé de préparation et leur application dans le domaine thérapeutique
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
WO2000021951A1 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465A1 (fr) * 2009-09-01 2011-03-04 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
WO2011150380A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012168411A1 (fr) * 2011-06-09 2012-12-13 Pierre Fabre Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A randomised controlled trial of bumetanide in the treatment of autism in children;E Lemonni等;《Translatonal Psychiatry》;20121201;第2卷(第12期);摘要 *
Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice;Aubin Michalon等;《Neuron》;20120401;第74卷(第1期);第49页右栏第1段 *
Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic Disorder;King B H等;《Journal of the American Academy of Child & Adolescent Psychiatry》;20010630;第40卷(第6期);摘要 *

Also Published As

Publication number Publication date
KR102280530B1 (ko) 2021-07-21
SI3079688T1 (en) 2018-03-30
US10028948B2 (en) 2018-07-24
NZ720868A (en) 2022-04-29
AU2014363428B2 (en) 2019-09-12
AU2014363428A1 (en) 2016-06-23
CA2932791C (en) 2021-11-09
RU2686110C1 (ru) 2019-04-24
ES2657706T3 (es) 2018-03-06
JP6419826B2 (ja) 2018-11-07
DK3079688T3 (da) 2018-01-29
KR20160088886A (ko) 2016-07-26
MX372922B (es) 2020-04-27
PL3079688T3 (pl) 2018-05-30
PT3079688T (pt) 2018-02-28
NO3079688T3 (enExample) 2018-04-21
MY172937A (en) 2019-12-16
CY1119907T1 (el) 2018-06-27
HRP20180323T8 (hr) 2019-01-25
LT3079688T (lt) 2018-02-12
IL245996B (en) 2018-11-29
WO2015086836A1 (en) 2015-06-18
HRP20180323T1 (hr) 2018-04-06
SA516371298B1 (ar) 2018-06-07
US20160303117A1 (en) 2016-10-20
TN2016000213A1 (en) 2017-10-06
EP3079688A1 (en) 2016-10-19
HK1223563A1 (zh) 2017-08-04
HUE036035T2 (hu) 2018-06-28
CN105792824A (zh) 2016-07-20
MX2016007612A (es) 2016-09-09
EP3079688B1 (en) 2017-11-22
BR112016012552A8 (pt) 2022-11-08
UA117271C2 (uk) 2018-07-10
IL245996A0 (en) 2016-07-31
JP2016540000A (ja) 2016-12-22
CA2932791A1 (en) 2015-06-18
RU2019104946A (ru) 2019-04-01
RS56931B1 (sr) 2018-05-31
MA39076A1 (fr) 2017-05-31

Similar Documents

Publication Publication Date Title
CN105792824B (zh) 色酮衍生物作为多巴胺d3受体拮抗剂用于治疗自闭症谱系障碍的用途
Higashida et al. CD38 and its role in oxytocin secretion and social behavior
Higashida et al. Social memory, amnesia, and autism: brain oxytocin secretion is regulated by NAD+ metabolites and single nucleotide polymorphisms of CD38
Powell et al. Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice
BR112021002654A2 (pt) uso de roluperidona para tratar sintomas e distúrbios negativos, aumentar a neuroplasticidade e promover neuroproteção
Dell’Osso et al. Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options
US20130164367A1 (en) Treatment of neurodegenerative disease with creb-binding protein
Pozzer et al. Clinical-grade intranasal NGF fuels neurological and metabolic functions of Mecp2-deficient mice
CN109563089A (zh) 促进app正常加工的化合物
Sakai et al. An attempt of non-human primate modeling of schizophrenia with neonatal challenges of epidermal growth factor
HK1223563B (zh) 色酮衍生物作为多巴胺d3受体拮抗剂用於治疗自闭症谱系障碍的用途
OA17906A (en) A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder.
Prananjaya et al. DRD2 Gene Polymorphisms in Schizophrenia Patients
WO2022047212A1 (en) Compositions and methods for treating neurodegenerative disorders
Miura et al. PM516. Association of DNA Methylation of Taq1A in the DRD2 with Response to Aripiprazole in acute schizophrenia
RU2812786C2 (ru) Применение ролуперидона для лечения негативных симптомов и заболеваний, повышения нейропластичности и содействия нейрозащите
Yossif et al. Poison Severity Score of Accidental Acute Pediatric Intoxication among Cases Presenting to the Pediatric Department in Damietta General Hospital
TW201035081A (en) Novel pharmaceutical composition for treatment of schizophrenia
US11840731B2 (en) Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus
Ojha et al. A Discursive Examination of the Neurodegenerative Alzheimer's Disease. Clin Pharmacol Biopharm, 11: 305
Ivanova et al. PM515. The association between serotonin receptor gene polymorphisms and hyperprolactinemia in antipsychotic drug-treated schizophrenic patients
Rivera Rewarding Effects of Ethanol
HK40094114A (en) Medicine for alleviating neuropathic pain
Nandakumar Autism–A Neurological Disorder in Children
Kumar A SELECTIVE SUMMARY OF PSYCHOPHARMACOLOGY RESEARCH PUBLISHED IN 2016

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1223563

Country of ref document: HK

GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180803